Lecture Details - Overview

View all Online CME

Continuing Education Information

Physicians' Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource designates this educational activity for a maximum of 28 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

SOBO Online

Release Date: December 31, 2009| Expiration Date: September 30, 2010
28 AMA PRA Category 1 Credit(s)™| Dec 31, 2009 - Sep 30, 2010, Atlanta, GA

Lecture Overview

Over the past decade, an increasing number of oncologists have concentrated their practices on breast cancer. In order to advance patient care, the School of Breast Oncology was developed. This curriculum-based program focuses exclusively on breast cancer clinical management. This intensive 4-day interactive educational course will provide a comprehensive review of the existing data on the most important aspects of breast cancer biology, diagnostics, prevention, and treatment. The curriculum will be evidence based, summarizing the existing data for each topic and applying these data to patient cases. This educational program is directed toward medical, radiation, and surgical oncologists whose primary practice focus is breast cancer and who intend to reinforce their knowledge base and expand their expertise in breast cancer diagnosis, treatment, and management. Participants will be primarily oncologists or fellows in training whose practice requires mastery and a critical understanding of the fundamental principles, pivotal published studies, and emerging information on the pathogenesis and management of breast cancer.

At the conclusion of this school, you should be able to:

  • Discuss breast carcinogenesis and the impact of germline mutations on patient management
  • Explain the clinical utility and limitations of sentinel lymph node biopsy
  • Integrate current staging guidelines into clinical decision making regarding local and systemic therapies
  • Discuss advances in breast cancer imaging and early detection, including mammography, ultrasound, MRI, and PET scanning
  • Integrate prognostic and predictive factors for breast cancer into patient management decisions and assess the optimal means of HER2 and hormone receptor expression analysis
  • Assess optimal radiation therapy strategies for treatment of patients with DCIS, early-stage, and locally advanced breast cancer
  • Critically analyze the data guiding the choice of adjuvant chemotherapies, endocrine therapies, or targeted agents for patients with low- and high-risk breast cancer and for elderly patients
  • Evaluate the evidence guiding treatment recommendations for the management of patients with hormone-dependent and hormone-independent metastatic breast cancer
  • Evaluate organ-specific therapeutic interventions for patients with metastatic disease to the CNS and skeleton
  • Integrate palliative care strategies into treatment algorithms for metastatic disease
  • List novel chemotherapies and targeted agents currently under evaluation for the treatment of advanced and early-stage breast cancer
  • Describe current and emerging strategies for ameliorating or eliminating therapy-associated adverse events
  • Assess the evidence supporting an emphasis on quality of life and rehabilitation during and after breast cancer treatment
  • Refer appropriate patients to promising clinical trials

Instructions for Participation

  1. Read the following information before registering for the educational activity.
  2. After you have registered, you will receive your username and password via e-mail.
  3. Click here to access the online lectures and the CME test.
  4. Complete the pretest.
  5. View and study the Flash video presentations for the selected module.
  6. Take the examination for the selected module.
  7. Indicate time spent viewing the presentations and completing the examination for each module
  8. After successful completion of the pretest and module examination, you will be able to download and print your certificate. Once you request a certificate, you will not be allowed to reenter the activity to complete additional modules for credit.
  • CME credit will be granted for online participation only. If you attended the live activity, you are not eligible for additional credit.
  • You will have 2 opportunities to answer each question correctly.
  • Successful completion of each module is determined by a score of 65% or greater on the module examination.

Complete the test(s) and evaluation by September 30, 2010 to receive your certificate online.

Read all of the conditions in the Activity Terms box below. You must accept the CME Activity Terms in order to continue:

Disclosure Policy
It is the policy of Physicians’ Education Resource to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Physicians' Education Resource requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. Physicians' Education Resource has implemented a mechanism to identify and resolve all conflicts of interest prior to the activity.

These persons involved in the influence or control of content for the presentations from School of Breast Oncology have disclosed the following relationship with the companies listed. The PER Scientific Content Team has no relevant financial relationships to disclose, unless noted below individually.

D. Craig Allred, MD
No relevant financial relationships to disclose           

Douglas Arthur, MD
Paid Consultant/ Advisory Board – SenoRx

Harold Burstein, MD, PhD
No relevant financial relationships to disclose           

Rowan Chlebowski, MD, PhD
Research Funding – Amgen
Paid Consultant/Advisory Board –  Amgen, Eli Lilly and Company, Pfizer Inc.
Speaker’s Bureau – Agendia, AstraZeneca, Novartis Pharmaceuticals Corporation, sanofi-aventis U.S.

David M. Euhus, MD, FACS
No relevant financial relationships to disclose           

Carol Fabian, MD
Research Funding – Novartis Pharmaceuticals Corporation, ImClone Systems Incorporated

Stefan Glück, MD, PhD
Research Funding – Abraxis BioScience, LLC, Eli Lilly and Company, Genentech, Inc., Genomic Health, Inc., Novartis Pharmaceuticals Corporation, Roche Pharmaceuticals
Paid Consultant/Advisory Board –  Abraxis BioScience, LLC, Eli Lilly and Company, Genentech, Inc., Genomic Health, Inc., GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Pfizer Inc., Roche Pharmaceuticals, sanofi-aventis U.S.
Speaker’s Bureau – Abraxis BioScience, LLC, Eli Lilly and Company, Genentech, Inc., Genomic Health, Inc., GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Pfizer Inc., Roche Pharmaceuticals, sanofi-aventis U.S.

William J. Gradishar, MD, FACP
No relevant financial relationships to disclose           

Syed A. Hoda, MD
No relevant financial relationships to disclose           

Frankie Ann Holmes, MD, FACP
Speaker’s Bureau – Bristol-Myers Squibb Company; Genentech, Inc.

Claudine Isaacs, MDCM, FRCP(C)
Speaker’s Bureau – Abraxis BioScience, LLC; Genentech, Inc.; GlaxoSmithKline; Novartis Pharmaceuticals Corporation; Pfizer Inc.

Steven J. Kronowitz, MD, FACS
No relevant financial relationships to disclose           

Henry Kuerer, MD, PhD, FACS
No relevant financial relationships to disclose           

Nancy Uan-Tsin Lin, MD
No relevant financial relationships to disclose           

Jennifer Litton, MD
No relevant financial relationships to disclose           

Charles Loprinzi, MD
No relevant financial relationships to disclose

Eleftherios Mamounas, MD, MPH, FACS
Paid Consultant/Advisory Board – Agendia, Genentech, Inc., Genomic Health, Inc., GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Pfizer Inc., sanofi-aventis U.S.
Speaker’s Bureau – Genentech, Inc.; Genomic Health, Inc.

Anne McTiernan, MD, PhD
Paid Consultant/Advisory Board – Merck & Co., Inc. (spouse)
Major Stock/Investment Holder – Merck & Co., Inc. (spouse)

Anne Moore, MD
No relevant financial relationships to disclose           

Joyce O’Shaughnessy, MD
Paid Consultant/Advisory Board – Amgen, Bristol-Myers Squibb Company, Genentech, Inc., Novartis Pharmaceuticals Corporation
Speaker’s Bureau – Abraxis BioScience, LLC; AstraZeneca; Bristol-Myers Squibb Company; Eli Lilly and Company; sanofi-aventis U.S.

Beth Overmoyer, MD, FACP
No relevant financial relationships to disclose           

Lori J. Pierce, MD
No relevant financial relationships to disclose           

Elizabeth A. Rafferty, MD
Research Funding – Hologic, Inc.

Peter Ravdin, MD, PhD
Employment – adjuvant, inc.
Board of Directors/Leadership Position – adjuvant, inc.; Major Stock/Investment Holder – adjuvant, inc.

Edward Romond, MD
No relevant financial relationships to disclose           

Hope S. Rugo, MD
Research Funding – Abbott Laboratories, Bristol-Myers Squibb Company, Genentech, Inc., GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Pfizer Inc., Roche Pharmaceuticals
Speaker’s Bureau – Genomic Health, Inc.

David M. Schuster, MD
Research Funding – Nihon Medi-Physics Co., Ltd.

Charles L. Shapiro, MD
Research Funding – Genentech, Inc.
Paid Consultant/Advisory Board – Genentech, Inc.

Thomas J. Smith, MD
Paid Consultant/Advisory Board – Medtronic, Inc.; United HealthCare Services, Inc.; Blue Cross Blue Shield

Lawrence J. Solin, MD, FACR
No relevant financial relationships to disclose 

Anthony Tolcher, MD
Paid Consultant/Advisory Board – Abraxis BioScience, LLC; ACT Biotech Inc.; Adnexus; Adventrx Pharmaceuticals, Inc.; Ambit Biosciences; Amgen; Applied Molecular Evolution/Eli Lilly and Company; ARIAD Pharmaceuticals, Inc.; Arresto Biosciences™; Astellas Pharma Inc.; AstraZeneca UK Limited; AVEO Pharmaceuticals, Inc.; Bayer Pharmaceuticals Corporation; Biogen Idec; BiPar Sciences, Incorporated; Calando Pharmaceuticals Inc.; Calistoga Pharmaceuticals, Inc.; Chemokine Therapeutics Corp.; Curis Inc.; Daiichi Sankyo, Company, Ltd.; Dendreon Corporation; Endo Pharmaceuticals; Enzon Pharmaceuticals, Inc.; Exelixis, Inc.; Five Prime Therapeutics, Inc.; Genentech, Inc.; Genta Incorporated; Geron; GlaxoSmithKline; HUYA Bioscience International; Intellikine; Johnson & Johnson Services, Inc.; Merck & Co., Inc.; MethylGene Inc.; Micromet, Inc.; Myriad Genetics, Inc.; Nektar; Nerviano Medical Sciences; Onyx Pharmaceuticals, Inc.; Pfizer Inc.; ProNAi Therapeutics, Inc.; Regeneron Pharmaceuticals, Inc.; sanofi-aventis U.S.; Santaris Pharma A/S; Schering-Plough Corporation; Seattle Genetics, Inc.; Semafore Pharmaceuticals, Inc.; Symphogen A/S; Veeda Clinical Research, Inc.

Catherine Van Poznak, MD
Research Funding – Amgen, Novartis Pharmaceuticals Corporation

Jeffrey Weitzel, MD
Speaker’s Bureau – Myriad Genetics, Inc.

This CME activity might include discussion of investigational and/or unlabeled uses of drugs. If the activity includes discussion of investigational and/or unlabeled uses of a drug, specific information is delineated by the faculty during the presentation. Please refer to the full prescribing information for each drug discussed in this activity for FDA-approved dosing, indications, and warnings.

Software Requirements
The Web pages and Web-based applications require a minimum Web browser of Microsoft Internet Explorer 5.5 or higher, Mozilla Firefox 1.0 or higher, or another compatible Web browser.

If you are not sure of the version of your browser, select Help in the menu bar of your browser, then select About.

PC Users
If you need to upgrade your Web browser, follow one of the links listed below:

Macintosh Users
Compatible Web browsers include

Disclaimer
The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views of the sponsor, supporter, or publisher. Although great care has been taken in compiling and checking the information given in this activity to ensure accuracy, the faculty and Physicians' Education Resource and its servants or agents shall not be responsible or in any way liable for the continued currency of the information or for any errors, omissions, or inaccuracies in this activity, whether arising from negligence or otherwise howsoever or for any consequences arising therefrom.

Please consult full prescribing information for any drugs or procedures discussed within.

Privacy Policy
Physicians' Education Resource (PER) makes reasonable efforts to ensure that privacy issues are handled responsibly. PER does not sell or share your information with other organizations that are not directly involved in this process. If you have further concerns, you may contact us at (888) 949-0045.

All rights reserved. No part of this activity may be translated, reproduced, stored, or transmitted by any means or in any type of media form including electronic, mechanical photocopying, recording, broadcasting, or otherwise without prior permission from the publisher.

©Copyright 2009 by Physicians' Education Resource. No material may be reproduced in whole or in part, in any form, without written permission from the publisher.

All correspondence should be directed to:
Editor, School of Breast Oncology
Physicians’ Education Resource
3500 Maple Ave.
Suite 700
Dallas, TX 75219
Phone: (214) 367-3456
Fax: (214) 367-3304
E-mail: editor@pergrouplp.com

110-2190

Educational Grants

An educational grant for this activity was provided by:


  1. Genentech BioOncology
  3. Bristol-Myers Squibb
  4. Eli Lilly and Company
  6. AstraZeneca
  7. Novartis Oncology